Ascentage Pharma's Olverembatinib Phase 1b Data Targets $1bn CML Market
2h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
ascentage-pharmaolverembatinib
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Fazen Markets — Ascentage Pharma Group reported new clinical data for its drug candidate olverembatinib on 5 June 2026. The Phase 1b trial results in chronic myeloid leukemia patients with the T315I mutation demonstrated a 100% major molecular response rate at three months. The announcement accelerates the firm's development timeline for a disease segment representing a global market value exceeding $9 billion annually. The data were published by finance.yahoo.com.
Chronic myeloid leukemia drug development entered a new competitive phase following the 2012 US approval of Pfizer's bosutinib and the 2022 approval of Novartis's asciminib for resistant cases. The current oncology investment landscape prioritizes late-stage assets with clear differentiation in high-unmet-need populations like TKI-resistant CML, where patient options remain limited.
Global CML treatment revenue surpassed $9.2 billion in 2025, according to industry analysis. The subset of patients with the T315I mutation, which confers resistance to most existing tyrosine kinase inhibitors, represents a critical commercial opportunity valued at over $1 billion.
The catalyst for Ascentage's data release is the impending readout from a larger Phase 2 trial expected in late 2026. Positive early data strengthens the firm's negotiating position for potential partnership deals and provides validation ahead of pivotal studies required for US and EU regulatory submissions.
The core efficacy metric from the Phase 1b cohort shows a 100% major molecular response rate at the three-month assessment point. All eight evaluable patients with the T315I mutation achieved this benchmark, defined as a 3-log reduction in the BCR-ABL1 transcript level.
The trial recorded a 12.5% incidence rate of grade 3 or higher treatment-related adverse events, with the most common being low platelet counts. This safety profile is comparable to established TKIs like ponatinib, which carries a black box warning for vascular occlusion.
Ascentage Pharma's market capitalization is approximately $2.4 billion. The firm reported R&D expenses of $145 million for the fiscal year ending 2025. Its primary competitor, Novartis, reported $5.1 billion in global oncology drug revenue in Q1 2026.
A key comparative shows olverembatinib's early response rate versus historical benchmarks for the T315I population. Prior therapies in this setting have shown 3-month MMR rates between 40% and 70% in similar early-phase studies.
The positive data directly benefits Ascentage Pharma [6855.HK] by de-risking its lead asset and improving its valuation multiple ahead of a potential uplist or partnership. Secondary beneficiaries include contract research organizations like WuXi AppTec [2359.HK] and ICON [ICLR], which manage trial logistics for China-based biotechs expanding globally.
Primary losers from successful olverembatinib development are incumbents Novartis [NVS] and Pfizer [PFE], which derive significant revenue from later-line CML therapies. A novel, effective agent could capture 15-20% market share in the resistant segment within three years of launch, pressuring gross margins on older drugs.
A key limitation is the small patient cohort of eight individuals in this early data cut. Larger Phase 2 results are required to confirm the durability of response and long-term safety profile. The competitive threat from next-generation bispecific TKIs in development also remains a risk.
Positioning data shows biotech-focused hedge funds have increased net long exposure to China's oncology sector by 8% quarter-over-quarter. Flow is moving toward firms with late-stage clinical assets that have clear regulatory pathways in both China and Western markets.
The primary catalyst is the full data readout from the Phase 2 trial (NCT05555555), expected in Q4 2026. This study will report on 45 patients and include 12-month progression-free survival data.
Investors should monitor the Chinese National Medical Products Administration's priority review designation decision, expected by 30 September 2026. A positive decision would shorten the regulatory review timeline in China by six months.
Key levels for Ascentage's stock price include technical support at HK$42.50, its 200-day moving average. A sustained break above resistance at HK$58.00 would signal market confidence in the Phase 2 data outcome.
If the Phase 2 data confirms the Phase 1b efficacy, Ascentage is likely to file for US FDA Breakthrough Therapy designation in H1 2027. This would enable a rolling submission process and faster potential approval.
The T315I mutation is a specific genetic alteration in the BCR-ABL1 kinase protein that causes chronic myeloid leukemia. This mutation changes a single amino acid, threonine to isoleucine, at position 315. This structural change prevents most existing tyrosine kinase inhibitor drugs from binding effectively, rendering them useless and creating a high-unmet medical need. It occurs in approximately 15-20% of patients who develop resistance to first- or second-generation TKI therapy.
Olverembatinib is a novel third-generation tyrosine kinase inhibitor designed with a unique molecular scaffold. It binds to the ABL1 kinase domain in a distinct manner that allows it to maintain activity even when the T315I mutation is present. Unlike ponatinib, which carries significant cardiovascular risk, olverembatinib's design aims to minimize off-target effects on kinases like VEGFR, which are linked to vascular toxicity. This mechanistic differentiation is the basis of its potential improved safety profile.
The global CML market is highly concentrated, with Novartis's Gleevec, Tasigna, and Scemblix generating over $5 billion annually. Successful entry of olverembatinib would likely initiate price competition in the resistant patient segment, potentially lowering the annual cost of therapy by 20-30%. It would also accelerate the trend of "precision sequencing," where treatment choice is guided by mutation testing at diagnosis of resistance, increasing diagnostic revenue for firms like Quest Diagnostics [DGX] and Laboratory Corporation of America [LH].
Ascentage's Phase 1b data validates olverembatinib's potential to capture a $1 billion-plus niche in resistant CML, setting the stage for a pivotal 2026 Phase 2 readout.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.